Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Deal Watch: BMS Licenses Bispecific TCR Candidate From Immatics

Deal Watch 2021

Related Content

MS Pharma Takes MENA Rights To Lucentis Rival

Dec 14 2021

Immatics To Go Public Through Merger With ‘Blank Check’ Company Arya

Mar 18 2020

Ipsen Gives Genfit Liver Drug New Lease Of Life

Dec 17 2021

Novartis Plumps For Share Buybacks Before Bolt-On M&A

Dec 16 2021

CSL Makes $11.7bn Move On Vifor Pharma In Renal Disease Push

Dec 14 2021

Lilly Furthers Precision Cancer Ambitions With Foghorn Collaboration

Dec 13 2021

Pfizer Buys Arena For $6.7bn In Bid To Diversify In Inflammation & Immunology

Dec 13 2021

Immatics' T-Cell Redirecting Immunotherapies Impress In Solid Tumors

Mar 18 2021

Related Companies

Immatics N.V.

Bristol Myers Squibb Company

Celgene Corporation

BioMarin Pharmaceutical Inc.

Myrtelle Inc.

Pfizer Inc.

Theriva Biologics, Inc.

VCN Biosciences SL

Alpine Immune Sciences Inc.

Horizon Therapeutics plc

Barinthus Biotherapeutics plc

Avidea Technologies, Inc.

Cerevel Therapeutics Holdings, Inc.

Assertio Holdings, Inc.

Antares Pharma, Inc.

Bionaut Labs

Candel Therapeutics, Inc.

MegaPharm Ltd.

SOM Biotech

Novartis AG

Molecular Partners AG

Biogen, Inc.

TheraPanacea

Additional Topics

Business Strategies Deals M & A Commercial Deal Watch BioPharmaceutical

More from Deal Watch

More from Deals

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window